Trials / Withdrawn
WithdrawnNCT00820768
A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies
A Phase I of ABI-010 (Nab-17-AAG) and ABI-007 (Abraxane) Administered Weekly in Patients With Advanced Non-Hematologic Malignancies
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine MTD and DLT of ABI-010 given weekly every three weeks followed by one week of rest (Cycle 1). Determine MLD and DLT in combination with ABI-007; to characterize the toxicities of ABI-010 alone and in combination with ABI-007.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABI-010 | 17-AAG and ABI-007 |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2013-04-01
- Completion
- 2014-04-01
- First posted
- 2009-01-12
- Last updated
- 2018-04-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00820768. Inclusion in this directory is not an endorsement.